Ewa Dabrowska-Zamojcin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ewa Dabrowska-Zamojcin has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Pawlik
Department of Physiology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland
18 shared publications - Leszek Domański
Pomeranian Medical University, Szczecin, Poland
10 shared publications - Krzysztof Safranow
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-204 Szczecin, Poland
7 shared publications - Violetta Dziedziejko
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
7 shared publications - Barbara Gawrońska-Szklarz
Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
4 shared publications - Grazyna Dutkiewicz
Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland
3 shared publications
Latest Publications
- 7 October 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (6) , 1600-1611
Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases
- 7 October 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (6) , 1600-1611
Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases
- Open Access
- 23 May 2017
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 66 (1) , 65-72
Ficolin-2 Gene rs7851696 Polymorphism is Associated with Delayed Graft Function and Acute Rejection in Kidney Allograft Recipients
Ficolin-2 is an activator of the complement system that acts via the lectin pathway. Complement activation plays a substantial role in the renal injury inherent to kidney transplantation. In this study, we examined the associations between ficolin-2 gene polymorphisms in exon 8 and kidney allograft function. This study comprised 270 Caucasian deceased-donor renal transplant recipients. The following parameters were recorded in each case: delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction. Among patients with DGF, we observed a significantly increased frequency of rs7851696 GT and TT genotypes as well as T allele (TT + GT vs GG OR 1.98, 95% CI 1.12–3.48, p = 0.02; T vs G OR 2.08, 95% CI 1.27–3.41, p = 0.005). There was also an increased frequency of rs4521835 GG and TG genotypes as well as G alleles; however, these differences were on the borderline of statistical significance (GG + TG vs TT, OR 1.75, 95% CI 0.98–3.12, p = 0.07; G vs T OR 1.45, 95% CI 1.00–2.09, p = 0.050). In addition, we observed an increased frequency of acute allograft rejection in carriers of ficolin-2 rs7851696 T alleles on the borderline of statistical significance (TT + GT vs GG OR 1.75, 95% CI 0.97–3.16, p = 0.08), but the frequency of T allele was significantly higher in patients with AR (T vs G OR 1.71, 95% CI 1.02–2.87, p = 0.048). The results of our study suggest that ficolin-2 rs7851696 gene polymorphism influences kidney allograft functions, with T allele increasing the risk of DGF and AR.
- 23 May 2017
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 66 (1) , 65-72
Open AccessFicolin-2 Gene rs7851696 Polymorphism is Associated with Delayed Graft Function and Acute Rejection in Kidney Allograft Recipients
Ficolin-2 is an activator of the complement system that acts via the lectin pathway. Complement activation plays a substantial role in the renal injury inherent to kidney transplantation. In this study, we examined the associations between ficolin-2 gene polymorphisms in exon 8 and kidney allograft function. This study comprised 270 Caucasian deceased-donor renal transplant recipients. The following parameters were recorded in each case: delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction. Among patients with DGF, we observed a significantly increased frequency of rs7851696 GT and TT genotypes as well as T allele (TT + GT vs GG OR 1.98, 95% CI 1.12–3.48, p = 0.02; T vs G OR 2.08, 95% CI 1.27–3.41, p = 0.005). There was also an increased frequency of rs4521835 GG and TG genotypes as well as G alleles; however, these differences were on the borderline of statistical significance (GG + TG vs TT, OR 1.75, 95% CI 0.98–3.12, p = 0.07; G vs T OR 1.45, 95% CI 1.00–2.09, p = 0.050). In addition, we observed an increased frequency of acute allograft rejection in carriers of ficolin-2 rs7851696 T alleles on the borderline of statistical significance (TT + GT vs GG OR 1.75, 95% CI 0.97–3.16, p = 0.08), but the frequency of T allele was significantly higher in patients with AR (T vs G OR 1.71, 95% CI 1.02–2.87, p = 0.048). The results of our study suggest that ficolin-2 rs7851696 gene polymorphism influences kidney allograft functions, with T allele increasing the risk of DGF and AR.
- Open Access
- 1 January 2017
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 63 (3) , 115-119
KCNJ11 and KCNQ1 Gene Polymorphisms Are Not Associated with Post-Transplant Diabetes Mellitus in Kidney Allograft Recipients Treated with Tacrolimus
Post-transplant diabetes mellitus (PTDM) is a metabolic disorder occurring after solid organ transplantation during the therapy with calcineurin inhibitors. ATP-sensitive potassium channels KCNJ11 and KCNQ1 play an important role in the regulation of insulin secretion by β cells and development of diabetes mellitus. Numerous studies have confirmed the association between KCNJ11 and KCNQ1 gene polymorphisms and type 2 diabetes. The aim of this study was to examine the association between KCNJ11 and KCNQ1 gene polymorphisms and posttransplant diabetes mellitus in kidney allograft recipients treated with tacrolimus. The study included 201 patients who received kidney transplants. The patients were subdivided into two subgroups: patients with PTDM (N = 35) and patients without PTDM (N = 166). The association between KCNJ11 and KCNQ1 gene polymorphisms and post-transplant diabetes was studied in three models of univariate Cox regression analysis, i.e., additive, dominant and recessive. In these three models there were no statistically significant associations between KCNJ11 and KCNQ1 gene polymorphisms and PTDM. The results of this study suggest lack of association between KCNJ11 and KCNQ1 gene polymorphisms and post-transplant diabetes mellitus in kidney allograft recipients treated with tacrolimus in the Polish population.
- 1 January 2017
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 63 (3) , 115-119
Open AccessKCNJ11 and KCNQ1 Gene Polymorphisms Are Not Associated with Post-Transplant Diabetes Mellitus in Kidney Allograft Recipients Treated with Tacrolimus
Post-transplant diabetes mellitus (PTDM) is a metabolic disorder occurring after solid organ transplantation during the therapy with calcineurin inhibitors. ATP-sensitive potassium channels KCNJ11 and KCNQ1 play an important role in the regulation of insulin secretion by β cells and development of diabetes mellitus. Numerous studies have confirmed the association between KCNJ11 and KCNQ1 gene polymorphisms and type 2 diabetes. The aim of this study was to examine the association between KCNJ11 and KCNQ1 gene polymorphisms and posttransplant diabetes mellitus in kidney allograft recipients treated with tacrolimus. The study included 201 patients who received kidney transplants. The patients were subdivided into two subgroups: patients with PTDM (N = 35) and patients without PTDM (N = 166). The association between KCNJ11 and KCNQ1 gene polymorphisms and post-transplant diabetes was studied in three models of univariate Cox regression analysis, i.e., additive, dominant and recessive. In these three models there were no statistically significant associations between KCNJ11 and KCNQ1 gene polymorphisms and PTDM. The results of this study suggest lack of association between KCNJ11 and KCNQ1 gene polymorphisms and post-transplant diabetes mellitus in kidney allograft recipients treated with tacrolimus in the Polish population.
- Open Access
- 25 October 2016
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 41 (3) , 255-259
STAT4 gene polymorphism in patients after renal allograft transplantation
Introduction: STAT4 (signal transducer and activator of transcription 4) is involved in the regulation of innate and adaptive immune responses. Some studies have suggested that STAT4 may be involved in the immune response after graft transplantation. Several polymorphisms in the STAT4 gene have been identified. The most commonly studied polymorphism in the STAT4 gene is rs7574865. In our study, we examined whether this polymorphism is associated with the early and late functions of renal allografts. Material and methods: A total of 270 recipients of first renal transplants were included in the study. Single nucleotide polymorphisms (SNPs) within the STAT4 gene were genotyped using TaqMan genotyping assays. Results: There were no statistically significant associations between the STAT4 gene rs7574865 polymorphism and delayed graft function, acute rejection, chronic allograft dysfunction, post-transplant diabetes mellitus, or creatinine serum concentrations after transplantation. Conclusions: Our results suggest a lack of association between the STAT4 rs7574865 SNP and kidney allograft function in the Polish population.
- 25 October 2016
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 41 (3) , 255-259
Open AccessSTAT4 gene polymorphism in patients after renal allograft transplantation
Introduction: STAT4 (signal transducer and activator of transcription 4) is involved in the regulation of innate and adaptive immune responses. Some studies have suggested that STAT4 may be involved in the immune response after graft transplantation. Several polymorphisms in the STAT4 gene have been identified. The most commonly studied polymorphism in the STAT4 gene is rs7574865. In our study, we examined whether this polymorphism is associated with the early and late functions of renal allografts. Material and methods: A total of 270 recipients of first renal transplants were included in the study. Single nucleotide polymorphisms (SNPs) within the STAT4 gene were genotyped using TaqMan genotyping assays. Results: There were no statistically significant associations between the STAT4 gene rs7574865 polymorphism and delayed graft function, acute rejection, chronic allograft dysfunction, post-transplant diabetes mellitus, or creatinine serum concentrations after transplantation. Conclusions: Our results suggest a lack of association between the STAT4 rs7574865 SNP and kidney allograft function in the Polish population.
- 1 March 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 32, 62-65
CCL2 gene polymorphism is associated with post-transplant diabetes mellitus
- 1 March 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 32, 62-65
CCL2 gene polymorphism is associated with post-transplant diabetes mellitus
- 26 November 2015
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 12 (1) , 41-55
The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy
Rheumatoid arthritis (RA) is a systemic disease leading to joint destruction. The therapy of RA is mainly based on disease modifying anti-rheumatic drugs (DMARDs) and biological drugs. The response to treatment is different among patients. Therefore, we have searched for factors that may predict the efficacy and toxicity during therapy in individual patients. Areas covered: This review presents the role of genetic polymorphisms as predictors of the efficacy and toxicity during the therapy of rheumatoid arthritis patients with disease modifying anti-rheumatic drugs (methotrexate, leflunomide, sulfasalazine) and biological drugs (anti-TNF-alpha antagonists, Tocilizumab, Rituximab) Expert opinion: Despite studies having shown an association between genetic polymorphisms and response to therapy in RA patients, the majority of these findings are still inconclusive and inconsistent. We are still far from applying pharmacogenetic tests in routine clinical practice that can predict the outcome of treatment. Several factors, such as small sample size with low statistical power, variability in the outcome definitions and the heterogeneity of the cohorts, limited number of tested single nucleotide polymorphisms (SNPs), small effect for the selected variant, and a lack of consideration of epigenetic factors, may contribute to the inconsistency observed and may lead to limited success in personalizing therapy.
- 26 November 2015
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 12 (1) , 41-55
The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy
Rheumatoid arthritis (RA) is a systemic disease leading to joint destruction. The therapy of RA is mainly based on disease modifying anti-rheumatic drugs (DMARDs) and biological drugs. The response to treatment is different among patients. Therefore, we have searched for factors that may predict the efficacy and toxicity during therapy in individual patients. Areas covered: This review presents the role of genetic polymorphisms as predictors of the efficacy and toxicity during the therapy of rheumatoid arthritis patients with disease modifying anti-rheumatic drugs (methotrexate, leflunomide, sulfasalazine) and biological drugs (anti-TNF-alpha antagonists, Tocilizumab, Rituximab) Expert opinion: Despite studies having shown an association between genetic polymorphisms and response to therapy in RA patients, the majority of these findings are still inconclusive and inconsistent. We are still far from applying pharmacogenetic tests in routine clinical practice that can predict the outcome of treatment. Several factors, such as small sample size with low statistical power, variability in the outcome definitions and the heterogeneity of the cohorts, limited number of tested single nucleotide polymorphisms (SNPs), small effect for the selected variant, and a lack of consideration of epigenetic factors, may contribute to the inconsistency observed and may lead to limited success in personalizing therapy.
- 1 June 2015
- Published by Elsevier in Transplant Immunology
- Vol. 32 (3) , 172-174
Association between the CX3CR1 gene V249I polymorphism and delayed kidney allograft function
- 1 June 2015
- Published by Elsevier in Transplant Immunology
- Vol. 32 (3) , 172-174
Association between the CX3CR1 gene V249I polymorphism and delayed kidney allograft function
- Open Access
- 3 June 2014
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 39 (1) , 58-64
Renalase Gene Polymorphism in Patients After Renal Allograft Transplantation
Background/Aims: Renalase is a recently discovered protein, which is likely involved in regulation of blood pressure in humans and animals. Previous studies suggest that renalase reflects kidney functioning. A common missense polymorphism in the flavin-adenine dinucleotide-binding domain of human renalase (Glu37Asp) has been described. In this study we examined the association between (Glu37Asp) polymorphism (rs2296545) in renalase gene and kidney allograft function. Methods: The study enrolled 270 Caucasian kidney allograft recipients. SNP within the renalase was genotyped using TaqMan genotyping assays. Results: There were no statistically significant associations between renalase gene rs2296545 polymorphism and delayed graft function, acute rejection, chronic allograft dysfunction as well as creatinine serum concentrations and blood pressure values after transplantation. Conclusions: The results of this study suggest, that renalase gene rs2296545 polymorphism is not important factor determining renal allograft function.
- 3 June 2014
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 39 (1) , 58-64
Open AccessRenalase Gene Polymorphism in Patients After Renal Allograft Transplantation
Background/Aims: Renalase is a recently discovered protein, which is likely involved in regulation of blood pressure in humans and animals. Previous studies suggest that renalase reflects kidney functioning. A common missense polymorphism in the flavin-adenine dinucleotide-binding domain of human renalase (Glu37Asp) has been described. In this study we examined the association between (Glu37Asp) polymorphism (rs2296545) in renalase gene and kidney allograft function. Methods: The study enrolled 270 Caucasian kidney allograft recipients. SNP within the renalase was genotyped using TaqMan genotyping assays. Results: There were no statistically significant associations between renalase gene rs2296545 polymorphism and delayed graft function, acute rejection, chronic allograft dysfunction as well as creatinine serum concentrations and blood pressure values after transplantation. Conclusions: The results of this study suggest, that renalase gene rs2296545 polymorphism is not important factor determining renal allograft function.
- 1 May 2014
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 15 (7) , 905-907
Highlights from the Latest Articles In Pharmacogenomics of Solid organ Transplantation
- 1 May 2014
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 15 (7) , 905-907
Highlights from the Latest Articles In Pharmacogenomics of Solid organ Transplantation
- 1 March 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (2-3) , 84-87
Association between IVS3 +17T/C CD28 gene polymorphism and the acute kidney allograft rejection
- 1 March 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (2-3) , 84-87
Association between IVS3 +17T/C CD28 gene polymorphism and the acute kidney allograft rejection